The World Bank lowered its China growth forecast for the year from 4.3 percent predicted in June to 2.7 percent due to the impact of the pandemic and property sector weaknesses on its economy.
The institution also slashed its forecast for next year from 8.1 percent down to 4.3 percent.
Many analysts believe that China's GDP growth target of around 5.5 percent for the year is now unattainable.
According to the World Bank, outbreaks and growth slowdowns in China have been followed by uneven recoveries.
Disruption to businesses has continued in China as cases surge and some restrictions remain in place.
Health officials have acknowledged that since bulk testing criteria were removed, official data no longer accurately reflect domestic infections.
The IMF forewarned last week that it will likely also reduce its predictions for China, blaming a sustained rise in cases.
The fund revised its growth forecast for China in October, lowering it to 3.2 percent this year, the lowest level in decades from the 4.4 percent it expected the previous year.
According to IMF chief Kristalina Georgieva, they are very likely to downgrade the growth projections for China, both for 2022 and 2023,
As China moves forward with the reopening, experts worry that it is ill-prepared to handle the next wave of diseases since millions of susceptible elderly people have not yet had all of the recommended vaccinations.


FDA Approves Mitapivat for Anemia in Thalassemia Patients
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



